We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Baboon Study Suggests Cancer-Related Genes Regulate LDL Cholesterol Levels

By LabMedica International staff writers
Posted on 30 May 2013
Genome analysis of baboons in a controlled feeding study identified four genes linked to control of the level of serum low-density lipoprotein cholesterol (LDL-c), a biomarker for risk of cardiovascular disease.

Investigators at the Texas Biomedical Research Institute (San Antonio, USA) had previously identified a cluster of quantitative trait loci (QTL) on baboon chromosome 11 for multiple related quantitative traits for serum LDL-c. More...
In the current study, they determined the level of LDL-c in the 1,500 animals in their baboon colony and selected three baboons with low LDL-c levels and three with high levels. The baboons were fed a high-cholesterol, high fat (HCHF) diet for seven weeks, after which hepatic whole genome expression profiling for LDL-c was performed.

Results published in the April 17, 2013, online edition of the Journal of Lipid Research revealed that three genes were differentially expressed in the low LDL-c animals and eight in high LDL-c animals in response to the HCHF diet. Seven genes (ACVR1B, CALCOCO1, DGKA, ERBB3, KRT73, MYL6B, and TENC1) showed discordant expression between the low and high LDL-c baboons.

Data obtained with gene array and high throughput sequencing technology enabled integration of microRNA (miRNA) and messenger RNA (mRNA) expression profiles, which showed that four candidate genes (ACVR1B, DGKA, ERBB3, and TENC1) were miRNA targets and that the miRNAs were inversely expressed to the target genes. The four genes are members of a signaling pathway known to be important for cell survival, and disruption of this pathway due to mutations in these genes has been associated with some types of cancer.

"Our findings are important because they provide new targets for the development of novel drugs to reduce heart disease risk in humans," said senior Dr. Laura Cox, associate scientist in genetics at the Texas Biomedical Research Institute. "Since these genes have previously been associated with cancer, our findings suggest that genetic causes of heart disease may overlap with causes of some types of cancer. That starts to give us the specific targets for new therapies. If all goes well, this information may be available within two years."

Related Links:
Texas Biomedical Research Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.